B
Baek Yeol Ryoo
Researcher at University of Ulsan
Publications - 85
Citations - 4878
Baek Yeol Ryoo is an academic researcher from University of Ulsan. The author has contributed to research in topics: Sorafenib & Population. The author has an hindex of 27, co-authored 85 publications receiving 3469 citations. Previous affiliations of Baek Yeol Ryoo include Asan Medical Center & Seoul National University Hospital.
Papers
More filters
Journal ArticleDOI
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
Journal ArticleDOI
Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial
Andrew X. Zhu,Joon Oh Park,Baek Yeol Ryoo,Chia Jui Yen,Ronnie T.P. Poon,Davide Pastorelli,Jean-Frédéric Blanc,Hyun Cheol Chung,Ari David Baron,Tulio Eduardo Flesch Pfiffer,Takuji Okusaka,Katerina Kubackova,Jörg Trojan,Javier Sastre,Ian Chau,Shao Chun Chang,Paolo Abada,Ling Yang,Jonathan D. Schwartz,Masatoshi Kudo +19 more
TL;DR: Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma and the safety profile is manageable.
Journal ArticleDOI
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Michael S. Lee,Baek Yeol Ryoo,Chih-Hung Hsu,Kazushi Numata,Stacey Stein,Wendy Verret,Stephen P. Hack,Jessica Spahn,Bo Liu,Heba Abdullah,Yulei Wang,Aiwu Ruth He,Kyung Hun Lee,Y-J. Bang,Johanna C. Bendell,Yee Chao,Jen-Shi Chen,Ho-Sun Chung,Samantha Davis,A. Dev,Edward Gane,Benson M. George,Aiwu R. He,H. Hochster,Chiun Hsu,Masanori Ikeda,J.W. Lee,Myung-Mook Lee,Amit Mahipal,Gulam Abbas Manji,Manabu Morimoto,K. Numata,Michael J. Pishvaian,Shukui Qin,David P. Ryan,Baek-Yeol Ryoo,N. Sasahira,S. Stein,John H. Strickler,Niall C. Tebbutt +39 more
TL;DR: Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-to-treat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1.
Journal ArticleDOI
Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study
Jeeyun Lee,Wing Yan Au,Min Jae Park,Junji Suzumiya,Shigeo Nakamura,Jun Ichi Kameoka,Chikara Sakai,Kazuo Oshimi,Yok-Lam Kwong,Raymond Liang,Harry Yiu,Kam Hung Wong,Hoi Ching Cheng,Baek Yeol Ryoo,Cheolwon Suh,Young Hyeh Ko,Kihyun Kim,Jae Won Lee,Won Seog Kim,Ritsuro Suzuki +19 more
TL;DR: HSCT seems to confer a survival benefit in patients who attained CR on postremission consolidation therapy, and patients in CR with high NKIPI risk scores at diagnosis should receive full consideration for HSCT.
Journal ArticleDOI
Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
Gwang Hyeon Choi,Ju Hyun Shim,M.-J. Kim,Min Hee Ryu,Baek Yeol Ryoo,Yoon-Koo Kang,Yong Moon Shin,Kang Mo Kim,Young-Suk Lim,Han Chu Lee +9 more
TL;DR: In this retrospective study, TACE plus sorafenib was superior to sorAFenib alone with respect to TTP in patients with advanced-stage HCC, although it may or may not improve OS.